NO20004966D0 - Anvendelse av anti-gp-39-antistoff ved behandling og/eller reversering av lupus og assosiert nyresykdom - Google Patents

Anvendelse av anti-gp-39-antistoff ved behandling og/eller reversering av lupus og assosiert nyresykdom

Info

Publication number
NO20004966D0
NO20004966D0 NO20004966A NO20004966A NO20004966D0 NO 20004966 D0 NO20004966 D0 NO 20004966D0 NO 20004966 A NO20004966 A NO 20004966A NO 20004966 A NO20004966 A NO 20004966A NO 20004966 D0 NO20004966 D0 NO 20004966D0
Authority
NO
Norway
Prior art keywords
lupus
reversal
antibody
treatment
kidney disease
Prior art date
Application number
NO20004966A
Other languages
English (en)
Other versions
NO20004966L (no
Inventor
Randolph J Noelle
Christopher M Burns
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of NO20004966D0 publication Critical patent/NO20004966D0/no
Publication of NO20004966L publication Critical patent/NO20004966L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO20004966A 1998-04-03 2000-10-02 Anvendelse av anti-gp-39-antistoff ved behandling og/eller reversering av lupus og assosiert nyresykdom NO20004966L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5448898A 1998-04-03 1998-04-03
PCT/US1999/007321 WO1999051258A1 (en) 1998-04-03 1999-04-02 USE OF ANTI-gp39 ANTIBODIES FOR TREATMENT AND/OR REVERSAL OF LUPUS AND ASSOCIATED KIDNEY DISEASE

Publications (2)

Publication Number Publication Date
NO20004966D0 true NO20004966D0 (no) 2000-10-02
NO20004966L NO20004966L (no) 2000-12-04

Family

ID=21991433

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004966A NO20004966L (no) 1998-04-03 2000-10-02 Anvendelse av anti-gp-39-antistoff ved behandling og/eller reversering av lupus og assosiert nyresykdom

Country Status (9)

Country Link
EP (1) EP1067954A4 (no)
JP (1) JP2002510643A (no)
KR (1) KR20010072564A (no)
CN (2) CN100352497C (no)
AU (1) AU743824B2 (no)
HU (1) HUP0101689A3 (no)
NO (1) NO20004966L (no)
TW (1) TWI224969B (no)
WO (1) WO1999051258A1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
UA123398C2 (uk) 2015-08-05 2021-03-31 Янссен Байотек, Інк. Виділене антагоністичне антитіло, яке специфічно зв'язує cd154, та фармацевтична композиція, яка його містить
KR102840867B1 (ko) 2017-05-24 2025-07-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
CN1247472A (zh) * 1997-01-10 2000-03-15 拜奥根有限公司 用抗cd40l化合物治疗狼疮性肾炎
WO1998039026A2 (en) * 1997-03-07 1998-09-11 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases

Also Published As

Publication number Publication date
HUP0101689A3 (en) 2004-08-30
CN1173735C (zh) 2004-11-03
CN1303301A (zh) 2001-07-11
CN1757413A (zh) 2006-04-12
TWI224969B (en) 2004-12-11
WO1999051258A1 (en) 1999-10-14
NO20004966L (no) 2000-12-04
EP1067954A4 (en) 2004-08-18
CN100352497C (zh) 2007-12-05
AU3379699A (en) 1999-10-25
EP1067954A1 (en) 2001-01-17
KR20010072564A (ko) 2001-07-31
HUP0101689A2 (hu) 2001-08-28
AU743824B2 (en) 2002-02-07
JP2002510643A (ja) 2002-04-09

Similar Documents

Publication Publication Date Title
NO20034437D0 (no) Gangliosid-assosierte rekombinante antistoffer og anvendelse derav ved diagnostikk og behandling av tumorer
PT1083889E (pt) Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas
EP1194927A4 (en) COMBINED COMPLETED AND DESCRIPTIVE MEDIUM AND USE IN ONE APPLICATION ON THE INTERNET AS ELECTRONIC BOOK
NO2005006I2 (no) Anvendelse av tomoksetin ved behandling av ADHD
DE69836272D1 (de) Versuchsanordnung zur bestimmung von analyten in körperflüssigkeiten
IL200404A (en) Conjugates of antibodies that bind 191p4d12(b)proteins and uses thereof for treating cancer
NO991700D0 (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
NO941440D0 (no) Oljebrönn-sementoppslemminger, fremstilling av oppslemmingene, samt anvendelse ved brönnsementering
NO20002846D0 (no) Inhaleringsanordning og fremgangsmÕte ved samme
NO983576L (no) Br°nnbehandlingsfluider og fremgangsmÕter
DK0745396T3 (da) Blodpumpe og anvendelse deraf
FI964078A7 (fi) Ultraäänen käyttö paperinvalmistuksen yhteydessä
DK1017408T3 (da) Anvendelse af tetrahydrolipstatin i behandling af diabetes type II
NO964075D0 (no) Immunoterapeutisk middel samt anvendelse derav
NO20033443D0 (no) Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser
FR2812197B1 (fr) Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
HUP0202048A3 (en) Use of alpha1betha1 integrin receptor inhibitors and tgf-betha1 inhibitors in the treatment of kidney disease
NO991160D0 (no) Sulfatholdige polysaccharider og anvendelser derav ved medisinsk behandling
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
NO951825D0 (no) Vannbasert hårbehandlingspreparat og anvendelse av dette
IS2207B (is) Karbósýklískt kirnisleifar hemisúlfat og notkun þess við meðhöndlun á veirusýkingum
NO20020207D0 (no) Biologiske materialer og fremgangsmåter som er nyttige ved diagnostisering og behandling av sykdom
NO20004966L (no) Anvendelse av anti-gp-39-antistoff ved behandling og/eller reversering av lupus og assosiert nyresykdom
FI964809A0 (fi) En utrustning foer tillverkning av taeckplaot
DE69803245D1 (de) Bilderzeugungsgerät und Bestimmung des angeschlossenen Geräts

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application